United States Drug Patent 7,939,516: Scope, Claims, Expiration, and Tri-Luma Patent Landscape

US 7,939,516 protects a topical oil-in-water emulsion containing the three active ingredients in Tri-Luma Cream: fluocinolone acetonide, hydroquinone, and tretinoin. Its principal commercial protection is directed to a specific manufacturing sequence and a defined excipient system, rather than to the three-active-ingredient combination alone. The patent issued May 10, 2011, and its enforceable term ended in 2024 based on the patent’s earliest priority framework. It therefore presents no current U.S. blocking patent risk, although its claims remain relevant to historical litigation, freedom-to-operate reviews, and formulation design-arounds.

What drug and formulation does US 7,939,516 protect?

US 7,939,516 covers a topical emulsion for hyperpigmented skin conditions containing:

Active ingredient	Claimed concentration
Fluocinolone acetonide	About 0.01 wt%
Hydroquinone	About 4 wt%
Tretinoin	About 0.05 wt%

The claimed combination corresponds to the active formulation historically marketed as Tri-Luma Cream. Tri-Luma is a prescription topical product indicated for the short-term treatment of moderate-to-severe melasma of the face when used with sun avoidance and sunscreen measures. The product was approved under FDA NDA 021112.[1]

The patent does not broadly claim every topical formulation containing these three ingredients. Its claims are concentrated in four technical areas:

A three-active-ingredient emulsion.
A defined sequence for combining the active ingredients.
Addition of the emulsifier after the aqueous and non-aqueous phases have been combined.
A specified excipient composition and oil-in-water cream structure.

What are the independent claims of US 7,939,516?

The patent has six principal independent claims: claims 1, 5, 6, 20, 21, and 24.

Claim	Principal subject matter	Commercial significance
1	Three-active-ingredient emulsion made through a heated two-phase process	Broad process-defined composition claim
5	Composition with specified active ingredients and excipient concentrations	Narrow formulation claim
6	Three-active-ingredient emulsion made without emulsifier during initial phase combination	Process-sequence claim
20	Fluocinolone acetonide and tretinoin added before emulsifier, hydroquinone afterward	More specific manufacturing sequence
21	Homogeneous emulsion containing the three actives and listed excipients	Broad composition claim
24	Oil-in-water cream emulsion	Narrow structural and dosage-form claim

Claims 2 through 4, 7 through 19, and 22 through 23 depend from these independent claims and add concentration, excipient, temperature, sequence, or dosage-form limitations.

How broad is claim 1?

Claim 1 is a product-by-process claim. It requires:

Fluocinolone acetonide, hydroquinone, and tretinoin as the active ingredients.
A topical medicated composition.
An emulsion.
An aqueous phase formed by heating water and at least one hydrophilic compound to 75 °C to 80 °C.
A non-aqueous phase formed by heating at least two hydrophobic compounds to approximately 75 °C to 80 °C.
Combination of the two phases.
Stirring and cooling.
Addition of the active ingredients during the stirring and cooling stage.
Addition of an emulsifier after the aqueous and non-aqueous phases are combined.
Homogenization.

The claim is broader than claim 5 because it does not require the full excipient list or exact active concentrations. It is narrower than a conventional composition claim because the manufacturing sequence is included in the claim language.

The phrase “active ingredients consisting of” excludes another pharmacologically active ingredient. It does not necessarily exclude additional inactive formulation materials, provided they do not alter the claim’s required composition and process characteristics.

What formulation does claim 5 cover?

Claim 5 is the most detailed quantitative formulation claim. It requires a composition “consisting essentially of” the following components:

Component	Weight percentage
Fluocinolone acetonide	0.01%
Hydroquinone	4%
Tretinoin	0.05%
Butylated hydroxytoluene	0.04%
Cetyl alcohol	4%
Citric acid	0.05%
Glycerin	4%
Magnesium aluminum silicate	3%
Methyl gluceth	5%
Methylparaben	0.18%
Glyceryl stearate, PEG stearate, or both	3.5%
Propylparaben	0.02%
Sodium metabisulfite	0.2%
Stearic acid	3%
Stearyl alcohol	4%

“Consisting essentially of” is materially narrower than “comprising.” It permits unlisted ingredients only if they do not materially affect the basic and novel characteristics of the claimed composition. A competing formulation using different preservatives, emulsifiers, stabilizers, or phase components could reduce exposure to claim 5 even if it retains the same three active ingredients.

What manufacturing process is protected?

The patent’s central technical distinction is the delayed emulsifier sequence.

Claimed process sequence

The principal sequence is:

Prepare an aqueous composition.
Prepare a non-aqueous composition.
Combine the phases without an emulsifier.
Cool the combined mixture.
Add fluocinolone acetonide and tretinoin.
Add the emulsifier.
Add hydroquinone.
Homogenize the mixture.

Claim 20 states the sequence most explicitly. Claim 14 requires the emulsifier to be added before hydroquinone. Claim 15 adds sodium metabisulfite before hydroquinone. Claims 16, 17, 18, and 19 add the 75 °C to 80 °C phase-preparation range, cooling step, hydroquinone-after-cooling limitation, and homogenization at approximately 50 °C.

The sequence appears directed to formulation stability. Hydroquinone is oxidation-sensitive, while tretinoin and fluocinolone acetonide can be affected by heat, light, oxygen, and phase conditions. The claimed process separates the high-temperature phase preparation from active-ingredient addition and places hydroquinone late in the process.

How do claims 6, 20, and 21 differ?

Claim 6: process-defined emulsion

Claim 6 requires that steps (a) through (c) occur in the absence of an emulsifier. It then requires addition of the three active ingredients and an emulsifier before homogenization. The claim allows the emulsifier to be added immediately after phase combination or during active-ingredient addition.

Claim 20: ordered active addition

Claim 20 is narrower. It requires:

Fluocinolone acetonide and tretinoin to be added first.
The emulsifier to be added after those two actives.
Hydroquinone to be added after the emulsifier.
Homogenization after hydroquinone addition.

A manufacturer that adds hydroquinone before the emulsifier could avoid the literal sequence required by claim 20, subject to the scope of other claims and any doctrine-of-equivalents analysis.

Claim 21: composition-focused coverage

Claim 21 is a homogeneous emulsion claim. It does not expressly recite the detailed heating or ingredient-addition sequence of claims 1, 6, and 20. It requires the three actives plus a group of inactive ingredients, including magnesium aluminum silicate, butylated hydroxytoluene, cetyl alcohol, stearic acid, stearyl alcohol, parabens, glycerol stearate or PEG stearate, methyl gluceth, glycerin, citric acid, and sodium metabisulfite.

Claims 22 through 24 narrow claim 21 to the approximate Tri-Luma concentrations, an oil-in-water emulsion, and an oil-in-water cream.

What is the patent scope by technical category?

Technical category	Claims	Scope assessment
Three-active combination	1, 6, 20, 21	Requires all three specified active ingredients
Exact active concentrations	4, 7, 22	Focused on 0.01%/4%/0.05% formulation
Excipient system	5, 8-13, 21-22	Strongest exposure for formulations closely matching Tri-Luma
Delayed emulsifier addition	1, 3, 6, 12-15, 20	Central manufacturing limitation
Heating conditions	1, 16	Requires approximately 75 °C to 80 °C phase preparation
Hydroquinone addition sequence	2, 3, 14, 15, 18, 20	Limits process ordering
Homogenization	1, 6, 19, 20	Required final processing step
Oil-in-water cream	23-24	Narrow dosage-form limitation

When did US 7,939,516 lose exclusivity?

US 7,939,516 was issued on May 10, 2011. Its term was governed by the 20-year patent term measured from the applicable earliest nonprovisional filing date, subject to patent-term adjustment and any statutory extensions.[2]

The patent’s effective U.S. term ended in 2024. The patent therefore should be treated as expired for current U.S. freedom-to-operate purposes, rather than as an active formulation barrier. Patent expiration does not remove the historical relevance of the claims to products manufactured or sold during the enforceable term.

The patent’s expiration also means that a later entrant generally does not need to challenge the patent through a Paragraph IV certification solely to launch a product after expiration. A Paragraph IV certification remains relevant only where another unexpired Orange Book-listed patent protects the reference product.

What is the Orange Book status of Tri-Luma and this patent?

Tri-Luma was approved under NDA 021112. FDA Orange Book listings are product-specific and must be evaluated against the current NDA record, not against patent claims in isolation.[1]

US 7,939,516 was associated with the Tri-Luma formulation and its manufacturing technology. Its practical Orange Book significance ended when the patent term expired. Orange Book listing does not extend patent duration, and FDA listing does not establish that every claim is infringed by every competing formulation.

The relevant regulatory distinction is:

Issue	Effect
FDA approval of Tri-Luma	Establishes the reference product and approved indication
Orange Book patent listing	Can require patent certification by an ANDA applicant
Patent expiration	Removes the patent as a continuing exclusion right
NDA exclusivity	Separate from patent rights and generally expired long before 2024
Formulation similarity	Does not alone establish patent infringement

Are Paragraph IV challenges relevant?

Paragraph IV litigation would have been relevant before expiration if an ANDA applicant sought approval for a three-active-ingredient cream and certified that an Orange Book-listed patent was invalid, unenforceable, or not infringed.

Potential challenge theories against this patent would have included:

Lack of written description for the full range of hydrophilic and hydrophobic compounds.
Obviousness based on known Tri-Luma-type combinations and conventional emulsion processing.
Indefiniteness in terms such as “immediately after,” “in the course of,” “about,” and “homogenous.”
Non-infringement based on a different emulsifier sequence.
Non-infringement based on different excipients or phase-processing temperatures.
Product-by-process distinctions based on a materially different final product or manufacturing route.

The strongest non-infringement strategy would have been to avoid the combination of the same active concentrations, the listed excipient system, and the delayed-emulsifier process. A formulation using the same actives but a different emulsion architecture could have reduced exposure to the narrower claims.

What generic entry risks exist for a Tri-Luma-equivalent product?

The historic risk depended on the product’s formulation and manufacturing process.

Proposed product design	Historical patent risk
0.01% fluocinolone acetonide, 4% hydroquinone, 0.05% tretinoin with the full listed excipients	High
Same actives and concentrations, but different emulsifier sequence	Moderate; claims 5, 21, and 22 would remain relevant
Same actives with materially different excipients	Lower against claim 5; claims 1, 6, and 20 require separate analysis
Different active concentration	Lower against claims 4, 7, and 22, but not necessarily against broader claims
Non-emulsion vehicle	Lower against all claims requiring an emulsion
Alternative order with hydroquinone added before emulsifier	Potentially avoids claims 14, 15, 18, and 20
Different phase temperatures and no delayed emulsifier	Potentially avoids process limitations in claims 1 and 16

Because the patent has expired, these distinctions now matter primarily for historical liability, residual litigation, patent-family analysis, and formulation-development records.

Does biosimilar risk apply to this patent?

No. Biosimilar provisions under the Biologics Price Competition and Innovation Act apply to biological products. Tri-Luma is a small-molecule topical drug containing three synthetic active ingredients. A competing product would generally proceed through an abbreviated new drug application or another small-molecule pathway, not a biosimilar application.[3]

The principal regulatory issues are pharmaceutical equivalence, therapeutic equivalence, topical formulation comparability, inactive-ingredient suitability, and bioequivalence requirements established by FDA.

Which companies are relevant to the competitive landscape?

The commercial reference product is Tri-Luma, historically associated with Galderma. The patent record is also relevant to the original patent owner and any successor assignees identified in USPTO assignment records.[4]

The competitive field includes:

Authorized or branded Tri-Luma products.
Compounded triple-combination creams.
Generic or abbreviated-approval products containing the same three active ingredients.
Alternative melasma products containing hydroquinone, tretinoin, corticosteroids, azelaic acid, or other depigmenting agents.
Dermatology manufacturers developing separate-component regimens rather than a fixed combination.

A separate-component regimen can avoid the fixed-combination claim requirement because claims 1, 6, 20, and 21 require a composition containing all three active ingredients. That strategy may create different regulatory, prescribing, adherence, and reimbursement issues.

Are there licensing deals associated with US 7,939,516?

The patent record can establish assignments and ownership changes, but it does not reliably establish private patent licenses. No license should be inferred solely from an assignment, commercialization arrangement, or NDA sponsorship.

For transaction analysis, the key distinction is between:

Patent ownership.
Commercial rights to Tri-Luma.
FDA sponsorship of NDA 021112.
Manufacturing rights.
Private licenses or covenants not to sue.

Only the first three categories are generally visible in public patent and FDA records. A private license could affect historical litigation exposure but would not revive an expired patent.

How strong is the patent estate for the Tri-Luma formulation?

The patent estate was strongest against a close copy of the marketed formulation using the same excipients and manufacturing sequence. It was weaker against:

A non-emulsion vehicle.
A different emulsifier system.
Different preservatives or stabilizers.
Different phase temperatures.
A different active-addition sequence.
Separate-component products.

The estate’s main weakness was claim dependency on process details. A competitor could potentially design around the delayed emulsifier sequence while retaining the same three actives. Claim 21 provided broader composition protection, but it still required a substantial set of excipients.

The estate’s current strength is effectively zero as an exclusion right in the United States because US 7,939,516 has expired. Its historical strength was moderate to high for an exact or near-exact Tri-Luma formulation and lower for materially redesigned formulations.

What geographic coverage does the patent provide?

US 7,939,516 provides rights only in the United States. It does not directly block manufacture, sale, or use in Canada, Europe, Japan, or other markets.

Foreign counterparts, if any, require separate review for:

Grant status.
Local patent term.
Supplementary protection certificates.
National claim scope.
Local litigation.
Local Orange Book or equivalent listing systems.
Patent-term adjustment or restoration.

U.S. expiration does not determine foreign expiration dates.

Key Takeaways

US 7,939,516 covers a Tri-Luma-type topical oil-in-water cream containing fluocinolone acetonide, hydroquinone, and tretinoin.
The core inventive focus is delayed emulsifier addition and the order in which the active ingredients are incorporated.
Claim 5 is the principal narrow formulation claim and recites a detailed excipient system.
Claims 1, 6, and 20 are product-by-process claims with substantial manufacturing limitations.
Claims 21 through 24 provide composition and dosage-form coverage for a homogeneous oil-in-water cream.
The patent’s U.S. term ended in 2024, eliminating current blocking-patent risk.
The product is a small-molecule topical drug, so biosimilar provisions do not apply.
Historical Paragraph IV exposure would have focused on obviousness, indefiniteness, product-by-process limitations, and formulation design-arounds.
A competing product using different excipients, a different emulsifier sequence, or a non-emulsion vehicle would have had stronger historical design-around arguments.
U.S. patent expiration does not resolve the status of foreign counterparts or unrelated patents covering Tri-Luma, manufacturing, or alternative formulations.

FAQs

What active ingredients are in the patented Tri-Luma formulation?

The claimed active ingredients are 0.01% fluocinolone acetonide, 4% hydroquinone, and 0.05% tretinoin.

Does US 7,939,516 cover hydroquinone alone?

No. The asserted claims require the three-active combination of fluocinolone acetonide, hydroquinone, and tretinoin.

Can a generic use the same three active ingredients with a different cream base?

Historically, a different cream base could reduce exposure to the narrow excipient claims, but the broader composition and process claims would still require analysis. The patent is now expired in the United States.

Is the patented formulation protected by FDA exclusivity?

No current FDA exclusivity should be inferred from the patent. FDA regulatory exclusivity and patent protection are separate rights, and the original NDA exclusivity period expired before the patent term.

Does patent expiration permit unrestricted copying of Tri-Luma?

Patent expiration removes US 7,939,516 as a patent barrier. A copy still requires compliance with FDA approval requirements, labeling rules, manufacturing controls, trademarks, trade dress, and any unrelated unexpired intellectual-property rights.

References

U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations; NDA 021112. FDA.
United States Patent and Trademark Office. (2011). U.S. Patent No. 7,939,516, Topical pharmaceutical compositions and methods of use thereof. USPTO.
U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biologic products. FDA.
United States Patent and Trademark Office. (n.d.). Patent Center and assignment search records for U.S. Patent No. 7,939,516. USPTO.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2003284353	⤷ Start Trial
Brazil	0314882	⤷ Start Trial
Brazil	PI0314882	⤷ Start Trial
Canada	2503539	⤷ Start Trial
China	1738587	⤷ Start Trial
Cyprus	1117292	⤷ Start Trial
Denmark	1562531	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,939,516

Summary for Patent: 7,939,516